Skip to main content

Table 3 Comparison between laboratory results at baseline and at the end of treatment among the studied patients

From: Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B

  At baseline At the end of treatment P value
Hemoglobin (gm/dl) 12.22 ± 1.6 11.25 ± 1.5 P < 0.001
WBCs × 103/ml 4.63 ± 1.5 4.63 ± 1.7 P = 1.0
Platelet count × 103/ml 92.5 (50.0–356) 105 (37.0–392) P = 0.26
ALT/ULN (folds) 1.255 (0.22–5.35) 0.67 (0.2–2.0) P < 0.001
AST/ULN (folds) 1.75 (0.4–5.85) 0.9 (0.25–7.0) P < 0.001
Serum albumin (gm/dl) 2.85 ± 0.4 3.23 ± 0.5 P < 0.001
Serum bilirubin (mg/dl) 1.37 (0.3–3.2) 1.2 (0.2–3.4) P = 0.019
I.N.R. 1.33 ± 0.24 1.38 ± 0.24 P = 0.16
Serum creatinine (mg/dl) 0.84 ± 0.2 0.89 ± 0.3 P = 0.08
AFP (IU/l) 10.8 (0.1–201) 5.8 (0.2–24) P < 0.001
  1. All parameters described as mean ± SD except platelet count, ALT/ULN, AST/ULN, serum bilirubin, and AFP as median (min–max)